Skip to content

Effect of dexmedetomidine (DEX) combined with ropivacaine in lumbar plexus block for postoperative analgesia in children's hip joint surgery

Effect of dexmedetomidine (DEX) combined with ropivacaine in lumbar plexus block for postoperative analgesia in children's hip joint surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035816
Enrollment
Unknown
Registered
2020-08-17
Start date
2020-08-31
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

development dysplasia of hip

Interventions

Ropivacaine Group:0.2% ropivacaine 0.5ml/kg (i.e. 1mg / kg) was used for ultrasound-guided L3-4 single point lumbar plexus block
Ropivacaine+0.5ug/kg DEX Group:The diluted dexmedetomidine was extracted according to 0.5ug/kg and added to 0.2% ropivacaine at 0.5ml/kg for ultrasound-guided single point lumbar plexus block
Ropivacaine+1ug/kg DEX Group:The diluted dexmedetomidine was extracted according to 1ug/kg and added to 0.2% ropivacaine at 0.5ml/kg for ultrasound-guided single point lumbar plexus block
Ropivacaine+IV.0.5ug/kg DEX Group:0.2% ropivacaine 0.5ml/kg (1mg / kg) was used for ultrasound-guided L3-4 single point lumbar plexus block. During the operation, 0.5ug/kg DEX was added into 100ml nor
Ropivacaine+IV.1ug/kg DEX Group:0.2% ropivacaine 0.5ml/kg (1mg / kg) was used for ultrasound-guided L3-4 single point lumbar plexus block. During the operation, 1ug/kg DEX was added into 100ml normal

Sponsors

Department of Anesthesiology, Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1) Consent to join the study and obtain informed consent; 2) The age ranged from 2 to 7 years (inclusive); 3) American Society of anesthesiologists (ASA) grade I-II; 4) Children diagnosed as developmental dysplasia of the hip undergoing open reduction, pelvic osteotomy and femoral osteotomy;

Exclusion criteria

Exclusion criteria: 1) Coagulation dysfunction or anticoagulant therapy; 2) Spinal deformity; 3) The puncture site had a history of infection; 4) Allergy to ropivacaine; 5) Neuromuscular diseases.

Design outcomes

Primary

MeasureTime frame
CHEOPS scores;

Secondary

MeasureTime frame
sufentanil dosage;Incidence of intraoperative hypotension;Incidence of postoperative hypotension;Incidence of bradycardia;Incidence of pruritus;Incidence of vertigo;

Countries

China

Contacts

Public ContactChen Moxi

Department of Anesthesiology, Shanghai Sixth People's Hospital

chanmx@163.com+86 18930174386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026